enGene Holdings Inc. (ENGN) vs MaxCyte, Inc. (MXCT)

A side-by-side comparison of enGene Holdings Inc. and MaxCyte, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ENGN

enGene Holdings Inc.

$122M

$1.83HealthcareDelayed quote: Oct 6, 2026, 12:15 PM EDT

MXCT

MaxCyte, Inc.

$112M

$1.05HealthcareDelayed quote: Oct 6, 2026, 12:15 PM EDT

Total return — ENGN vs MXCT

growth of $100 · dividends reinvested · last 3y

ENGN -90.7% (-54.6%/yr)MXCT -67.1% (-30.9%/yr)MXCT compounded faster over this window

ENGN MXCT

ENGN vs MXCT: by the numbers

•ENGN is the larger company ($122M vs $112M market cap).
•Both run net losses; ENGN's is the smaller (0.00% vs -114.77% net margin).

Metrics side by side

Valuation

Metric	ENGN	MXCT
P/S ratio	N/A	3.62
P/B ratio	0.53	0.71

Profitability

Metric	ENGN	MXCT
Gross margin	0.00%	79.43%
Operating margin	0.00%	-137.12%
Net margin	0.00%	-114.77%
ROE	-2.13%	-22.45%
ROIC	-1.78%	-19.83%

Growth (annualized)

Metric	ENGN	MXCT
Revenue CAGR (5Y)	N/A	1.46%
Total return CAGR (5Y)	N/A	-37.32%

Go deeper

Full ENGN analysis Full MXCT analysis Interactive comparison tool

Dig into the metrics

enGene ROE MaxCyte ROE enGene operating margin MaxCyte operating margin enGene revenue growth MaxCyte revenue growth enGene free cash flow MaxCyte free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.